SMA-Studie : der CNTF-Genotyp als potentieller Einflussfaktor auf den klinischen Verlauf der infantilen spinalen Muskelatrophie
Year: 2014
Type: dissertation
Study design: Observational Study
Abstract: This study examines the cytokine ciliary neurotrophic factor as a potential modifier of the clinical course of spinal muscular atrophy. The autosomal recessive infantile spinal muscular atrophy (SMA) is a common neuromuscular disorder. It is caused by a homozygous mutation of the SMN1 gene leading to a lack of SMN protein. This lack of protein results in a retrograde denervation of the neuromuscular junction, axonal degeneration and finally the loss of motor neurons in the spinal cord. Clinically, the course of SMA is highly variable. Based on disease onset and achieved motor milestones patients suffering from SMA can be divided into types 1-3. Type 1 is characterized by an early start within the first months of life. Patients die within a few months, most likely due to respiratory failure. In type 2 first symptoms occur no later than 18 months of age. These patients never reach the ability to walk. Finally, type 3 is characterized by a late onset, moderate disabilities and normal life expectancy. The most potential factor influencing the clinical course of SMA is a centromeric copy of the SMN gene, which is called SMN2. It partly compensates the lack of SMN protein. To stop the disease morphologically and functionally, it is necessary to re-innervate the denervated muscle fibers by terminal sprouting of adjacent axons´ ends. The cytokine ciliary neurotrophic factor (CNTF) is capable of regulating this process. A potential influence on the course of SMA has therefore been discussed particularly due to results from genetic mouse model studies. In humans a SNP in the CNTF gene occurs in 1-3% of the population resulting in a homozygous null mutation. This allows a comparison of disease course in SMA patients with and without CNTF protein to evaluate the potential influence of CNTF. Some previous studies have shown a significantly earlier onset of the disease in patients suffering from multiple sclerosis and amyotrophic lateral sclerosis carrying a CNTF null mutation. In this study, a large cohort of human SMA patients was tested for the first time. 276 patients diagnosed with SMA through molecular genetic analysis were included. The number of copies of the SMN2 gene was determined by multiplex ligation-dependent probe amplification (MLPA). The CNTF genotyping was performed using pyrosequencing. In addition, data concerning specific clinical features was collected. In our study 39,5% of the patients show a heterozygous CNTF genotype, 59% a homozygous wild-type and 1,5% showed a homozygous mutation. A total of four patients carry the CNTF null mutation. They belong to types SMA 1 and SMA 2. An excess of heterozygotes in the study group is striking. It results in a significant deviation of genotype distribution from Hardy-Weinberg´s equilibrium. This occurred in earlier studies as well. However, an association of certain CNTF genotypes and SMA types could not be detected. Concerning the parameter disease onset, the Kaplan-Meier analysis shows significant differences between the SMA types and the number of SMN2 copies. In contrast, there are no significant results regarding the CNTF genotypes. Furthermore, the number of SMN2 copies has also a significant influence on the survival of SMA patients. The CNTF genotype shows no such influence. For type 1 and 3 no significant influence of CNTF on the expression of clinical features was detected. Among type 2 patients the features tongue fibrillation and strength in the torso show strikingly small but not significant p-values. Due to the exploratory character of the study correction for multiple testing was applied. Overall, the results of this study do not indicate a strong influence of CNTF on the clinical course of SMA. Following this exploratory study, further studies should be designed to specifically concentrate on promising features. This is necessary to finally decide, if the CNTF genotype should be considered in an establishment of a patient´s prognosis and further treatment trials.
Source: RWTH Publications (RWTH Aachen)
Authors: Julia Hansmeier, Sabine Rudnik‐Schöneborn
Institution: RWTH Aachen University
Language: German
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W802657198
